Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 913-918

  Advani, Anjali S ^a   Rodriguez, Cristina ^a   Jin, Tao ^b   Jawde, Rony Abou ^a   Saber, Wael ^b   Baz, Rachid ^a   Kalaycio, Matt ^a   Sobecks, Ronald ^a   Sekeres, Mikkael ^a   Tripp, Barbara ^a   Hsi, Eric ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b CCF   (United States)

Author keywords

Acute myelogenous leukemia; C kit; MFI; Prognosis; Tyrosine kinase

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOGENETICS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 40749132899     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.08.019     Document Type: Article

References (30)

1. Miller K., and Daoust P. Clinical manifestations of acute myeloid leukemia. In: Hoffman R., Benz E.J., Shattil S.J., et al. (Eds). Hematology: basic principles and practice (2000), Elsevier, Philadelphia 2017-2018
2. Advani A.S. FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications. Curr Pharm Des 11 (2005) 3449-3457
3. Thiede C., Koch S., Creutzig E., Steudel C., Illmer T., Schaich M., et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107 (2006) 4011-4020
4. Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6 (1987) 3341-3351
5. Domen J., and Weissman I. Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, KitI/c-kit signaling the other. J Exp Med 192 (2000) 1707-1718
6. Lev S., Givol D., and Yarden Y. A specific combination of substrates is involved in signal transduction by the kit-encoded receptor. EMBO J 10 (1991) 647-654
7. Kindler T., Breitenbucher F., Marx A., Hess G., Gschaidmeier H., Gamm H., et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. Blood 101 (2003) 2960-2962
8. Linnekin D. Early signaling pathways activated by c-kit in hematopoietic progenitor cells. Int J Biochem Cell Biol 31 (1999) 1053-1074
9. Ikeda H., Kanakura Y., Tamaki T., Kuriu A., Kitayama H., and Ishikawa J. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78 (1991) 2962-2968
10. Wang C., Curtis J.E., Geissler E.N., McCulloch E.A., and Minden M.D. The expression of the proto-oncogene c-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3 (1989) 699-702
11. Kawakita M., Yonemura Y., Miyake H., Ohkubo T., Asou N., Hayakawa K., et al. Soluble c-kit molecule in serum from healthy individuals and patients with haematopoietic disorders. Br J Haematol 91 (1995) 23-29
12. Hu Q., Trevisan M., Xu Y., Wong W., Berger S.A., Lyman S.D., et al. C-kit expression enhances the leukemogenic potential of 32D cells. J Clin Invest 95 (1995) 2530-2538
13. Reuss-Borst M., Buhring H., Schmidt H., and Muller C.A. AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 8 (1994) 258-263
14. Smith F.O., Broudy V.C., Zsebo K.M., Lampkin B.C., Buckley C.V., Buckley J.D., et al. Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group. Blood 84 (1994) 847-852
15. Schwartz S., Heinecke A., Zimmermann M., Creutzig M., Schoch U., Harbott J., et al. Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. Leuk Lymphoma 34 (1999) 85-94
16. Del Poeta G., Venditti A., Del Principe M.I., Maurillo L., Buccisano F., Tamburini A., et al. Amount of spontaneous apoptosis detected by bax/bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101 (2003) 2125-2131
17. Kalaycio M., Pohlman B., Elson P., Lichtin A., Hussein M., Tripp B., et al. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 24 (2001) 58-63
18. He X.Y., Pohlman B., Lichtin A., Rybicki L., and Kalaycio M. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 17 (2003) 1078-1084
19. Byrd J.C., Mrozek K., Dodge R.K., Carroll A.J., Edwards C.G., Arthur D.C., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100 (2002) 4325-4336
20. Ashman L.K., Roberts M.M., Gadd S.J., Cooper S.J., and Juttner C.A. Expression of a 150 kDa cell surface antigen identified with monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukemia. Leuk Res (1988) 923-928
21. Lerner N.B., Nocka K.H., Cole S.R., Qiu F.H., Strife A., Ashman L.A., et al. Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 77 (1991) 1876-1883
22. Cheadle W.G., Hershman M.J., Wellhausen S.R., and Polk Jr. H.C. HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 161 (1991) 639-645
23. Graf M., Reif S., Hecht K., Pelka-Fleischer R., Pfister K., and Schmetzer H. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis. Am J Hematol 79 (2005) 26-35
24. Morabito F., Mangiola M., Oliva B., Stelitano C., Callea V., Deaglio S., et al. Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. Leuk Res 25 (2001) 927-932
25. Buhring H.J., Herbst R., Kostka G., Bossenmaier B., Bartke I., Kropshofer H., et al. Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia. Cancer Res 53 (1993) 4424-4431
26. Carson W.E., Haldar S., Baiocchi R.A., Croce C.M., and Caligiuri M.A. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci USA 91 (1994) 7553-7557
27. Sincock P.M., and Ashman L.K. Expression of c-kit and functional drug efflux are correlated in de novo acute myeloid leukaemia. Leukemia 11 (1997) 1850-1857
28. Tse W., Meshinchi S., Alonzo T.A., Stirewalt D.L., Gerbing R.B., Woods W.B., et al. Elevated expression of the AF1q gene, an MLL fusion partner, is and independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104 (2004) 3058-3063
29. Strunk C., Platzbecker U., Thiede C., Schaich M., Illmer T., Kang Z., et al. AF1q is a novel poor prognostic marker for adult acute myelogenous leukemia (AML) patients with normal cytogenetics. Blood 106 (2005) 921a
30. Kindler T., Breitenbuecher F., Marx A., Beck J., Hess G., Weinkauf B., et al. Efficacy and safety of imatinib in adult patients with c-kit positive acute myeloid leukemia. Blood 103 (2004) 3644-3654